The Journal of Immunology, Vol 150, Issue 10 4277-4283, Copyright © 1993 by American Association of Immunologists

ARTICLES

T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues

D Ostrov, J Krieger, J Sidney, A Sette and P Concannon
Department of Biological Structure, University of Washington School of Medicine, Seattle 98195.

A major objective of new rational immunosuppressive therapies is to be able to inhibit deleterious T cell responses in an Ag-specific manner. Recently, a novel approach to inducing Ag-specific nonresponsiveness in T cells, termed receptor or TCR antagonism, has been described. Several analogues of the influenza hemagglutinin (H3) peptide HA307-319 were shown to block recognition of the native HA307-319 peptide by a DR1- restricted T cell clone at concentrations 1,000- to 10,000-fold less than required to competitively inhibit HA307-319 binding to DR1. These Ag analogues that inhibited T cell recognition differed from the stimulatory antigenic peptide only at single positions. How such limited changes affect the ternary complex interactions of TCR, peptide, and DR remains unclear. In the present study, we have utilized two different DR5-restricted T cell clones that exhibit mutually exclusive specificities for HA peptides with or without substitutions at position 313 to investigate the molecular requirements for receptor antagonism. In this reciprocal model system, we show that a single peptide/DR complex can antagonize one T cell clone while stimulating another. A comparison of nucleotide sequences derived from the TCR of the T cell clones that were either antagonized or stimulated by the peptide analogue/DR5 complex indicated that the different responses of these T cells result from minor differences in the amino acid residues in junctional regions that most likely interact directly with position 313 of the peptide analogues. Our results suggest that TCR antagonism is an Ag-specific phenomenon in which T cells are inhibited by interactions involving TCR residues required for the recognition of conventional Ag and the altered residues in peptide analogues.

This article has been cited by other articles:

				J. Hennecke and D. C. Wiley Structure of a Complex of the Human {alpha}/{beta} T Cell Receptor (TCR) HA1.7, Influenza Hemagglutinin Peptide, and Major Histocompatibility Complex Class II Molecule, HLA-DR4 (DRA0101 and DRB10401): Insight into TCR Cross-Restriction and Alloreactivity J. Exp. Med., February 25, 2002; 195(5): 571 - 581. [Abstract] [Full Text] [PDF]

				A. M. Kalergis and S. G. Nathenson Altered Peptide Ligand-Mediated TCR Antagonism Can Be Modulated by a Change in a Single Amino Acid Residue Within the CDR3{beta} of an MHC Class I-Restricted TCR J. Immunol., July 1, 2000; 165(1): 280 - 285. [Abstract] [Full Text] [PDF]

				H. J. Hernandez and M. J. Stadecker Elucidation and Role of Critical Residues of Immunodominant Peptide Associated with T Cell-Mediated Parasitic Disease J. Immunol., October 1, 1999; 163(7): 3877 - 3882. [Abstract] [Full Text] [PDF]

				J. Vollmer, H. U. Weltzien, and C. Moulon TCR Reactivity in Human Nickel Allergy Indicates Contacts with Complementarity-Determining Region 3 but Excludes Superantigen-Like Recognition J. Immunol., September 1, 1999; 163(5): 2723 - 2731. [Abstract] [Full Text] [PDF]

				W ROSENBERG Mechanisms of immune escape in viral hepatitis Gut, May 1, 1999; 44(5): 759 - 764. [Full Text] [PDF]

				B H Hahn, R R Singh, and F M Ebling Self Ig peptides that help anti-DNA antibody production: importance of charged residues Lupus, June 1, 1998; 7(5): 307 - 313. [Abstract] [PDF]